Abstract: The present disclosure provides a coacervate composition containing a protein drug, gelatin A, sodium alginate and an acid and a wound-healing agent including the same. The coacervate composition according to the present disclosure can be useful as a wound-healing material delivery system for effectively delivering a protein drug, particularly epidermal growth factor, to a wound site in the wound-healing field.

Abstract: A personal care composition and methods for generating increased foam volume in the personal care composition are disclosed. The personal care composition may include a carrier and at least two hydrocolloids, wherein the at least two hydrocolloids are present in an effective amount to produce increased foam volume. The method may include contacting a carrier of the personal care composition with at least two hydrocolloids. The at least two hydrocolloids may include xanthan gum and carrageenan in a ratio of from about 1.5:1 to about 9:1.

Abstract: A method of treating or preventing dehydration in an individual having impaired swallowing such as dysphagia can include administering to the individual having the dysphagia an effective amount of a composition containing a salivating agent and a cooling agent in a weight ratio of 1:0.06 to 1:0.2. Optionally the composition includes a tingling agent. The composition can be a powder that is reconstituted before administration, for example at the point of consumption. A thickening or thin cohesive agent can be included in the powder and/or can be included in a liquid in which the powder is reconstituted. The composition can be a beverage containing the salivating agent and the cooling agent in a total amount of at least 3.0 wt. % of the beverage, for example at least 6.0 wt. % of the beverage. The composition can be a ready-to-drink beverage or a frozen dessert on a stick.

Abstract: Compositions are disclosed herein that comprise a mixture of at least one Albizia extract and a Magnolia extract. In some embodiments, the composition comprises a mixture of at least one Albizia extract enriched for one or more macrocyclic alkaloids and at least one Magnolia extract enrich for one or more lignans.

Abstract: The invention relates to new cationic polymers conjugated with D-fructose, as a result of which they can selectively interact with specific structure elements on cell surfaces. The problem was that of creating novel, biocompatible, easy-to-produce, D-fructose-conjugated cationic polymers that have a higher selectivity with respect to certain cell types. To solve this problem, the invention proposes cationic polymers with covalently bonded D-fructose of general formula (I) with the following components: a) cationic polymer: macromolecular compounds of n repeat units with one or more positive charges; b) linker: a unit that links the cationic polymer with D-fructose or derivatives of D-fructose by means of any alkyl or aryl group, any alkenyl or alkinyl group, an ether, thioether or amine, an ester, amide or other carboxylic acid derivative, a heterocycle (e.g.

Abstract: The invention relates to highly effective disinfecting or sterilising cloths with chlorine dioxide as the main active ingredient. For this, the chlorine dioxide is only generated shortly before use by bringing a cloth impregnated with a chlorite or chlorate salt in contact with a clearly defined amount of a suitable activation agent that is fluid or dissolved or admixed in a fluid, and prepackaged as a single dose, for the generation of chlorine dioxide. In a preferred embodiment, the impregnated cloth and the activation fluid are packaged in a common packaging unit and the activation occurs by breaking through a barrier separating the cloth or the cloths and the activation fluid. In a further preferred embodiment, the packaging is a moulded part having two packaging spaces separated from one another by removable barriers, which can be converted into a moulded part with only one chamber via simple pressure in one direction.

Abstract: Disclosed herein are linker architectures for conjugates that do not rely on the SAR of the cleavable trigger or the large steric bulk of a closely positioned antibody to alter payload release. These linkers are expected to reduce off-target payload release facilitated by extracellular cathepsins, and may also be applicable to conjugates of antibody fragments that lack the steric protection from a full antibody. In addition, the linkers disclosed herein are expected to provide more selective intracellular payload release. Thus, these linkers can function synergistically with the targeting vector to confer differential payload release rates in vivo that improve the selectivity of intracellular payload release and reduce off target toxicity.

Abstract: Disclosed herein is a novel compound of formula (I) for detecting circulating cancerous cells, particularly, cholangio-cancerous cells, from a biological sample, wherein, R1 and R2 are independently H, or —SO3M; and M is a monovalent cation selected from the group consisting of sodium ion, potassium ion, lithium ion or ammonium ion. Also disclosed herein is a method of treating and detecting cholangio-cancerous cells from a biological sample of a subject suspected of having cholangiocarcinoma (CCA). The method includes steps of, contacting the biological sample with a magnetic bead pre-coated with the compound of formula (I); detecting a complex formed between the magnetic bead and the biological sample in an immunoassay; and administering to the subject an effective amount of a chemotherapeutic agent to ameliorate symptoms associated with the CCA.

Abstract: The present invention provides an odor-modulating agent that modulates malodors generated in daily living environments or industries to different odors so that harm caused by the malodors can be easily solved, and an odor-modulating method. Specifically, the present invention provides an odor-modulating agent comprising at least one oxygen-containing cyclic compound selected from the group consisting of furan compounds, pyran compounds, and cyclopentanone derivatives.

Abstract: The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety of applications of the formulations of the invention. The subject invention includes novel soluble forms and various formulations of flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.

Abstract: Methods of reducing gingivitis and plaque buildup by administering an oral care product (a dentifrice or a mouthwash) that consists essentially of a sea salt, preferably Dead Sea salt, and xylitol. In mouthwash and dentifrice embodiments, the oral care product contains aloe vera leaf juice.

Abstract: The present disclosure relates to pyrrolobenzodiazepines (PBDs) having a labile C2 or N10 protecting group in the form of a linker to an antibody.

Abstract: The present invention relates to a tableted chewing gum composition for oral administration of cannabinoids, the composition comprising water-soluble chewing gum ingredients and water-insoluble gum base located in a plurality of particles, wherein the chewing gum composition comprises one or more cannabinoids, and wherein the chewing gum composition generates saliva and delivers more than 20% by weight of the one or more cannabinoids to the oral mucosa during the first 5 minutes of chewing.

Abstract: Field of application: the invention relates to biotechnology, can be used in the food industry, medicine and cosmetology in the prevention and/or treatment of diseases associated with immunodeficiencies and respiratory viral infections. The proposed food, cosmetic and pharmaceutical composition with an immunomodulating and protective antiviral effect additionally has the ability to completely prevent infection by a number of viruses, including influenza, rotavirus and coronavirus, as well as stimulate the immune system more than individual probiotics.

Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

Abstract: Collagen compositions, methods for preparing those collagen compositions, and 3D constructs formed from those collagen compositions are provided. In particular, methods of isolating collagen that exhibits an enhanced rate of gelling, such collagen compositions, and 3D constructs formed from such collagen compositions are provided.

Abstract: Filaments that contain a filament-forming material and an additive, nonwoven webs, and methods for making such filaments are provided.

Abstract: The present invention relates to an internal hole filler of an abutment for implant, which includes first polytetrafluoroethylene (first PTFE) and second polytetrafluoroethylene (second PTFE), wherein tensile strength measured after sintering the first PTFE is in a range of 20 MPa or more to less than 28 MPa, and tensile strength measured after sintering the second PTFE is 28 MPa or more, and a method of filling an internal hole of the abutment for implant.

Abstract: The invention relates primarily to a method of modulation, preferably of in vitro and/or in vivo modulation, of the cold menthol receptor TRPM8, wherein the receptor is contacted with at least one modulator selected from the group consisting of the compounds of the structure type 1 described herein. The present invention further relates to corresponding uses and compositions comprising such compounds.

Abstract: A method for treatment, prevention, or reduction of one-time or recurring viral outbreaks, for suppression of development or growth of chronic viral infections, or for prevention or treatment of viral infections, the method including, administering a synthetic lysine analog or mimetic, where the synthetic lysine analog or mimetic antagonizes or competes with an amino acid or other biological agent required by a virus to replicate or spread. Additionally, a composition to treat, prevent, or reduce one-time or recurrent viral outbreaks, suppress development or growth of chronic viral infections, or to prevent or treat viral infections, the composition including, a synthetic lysine analog or mimetic, where the synthetic lysine analog or mimetic antagonizes or competes with an amino acid or other biological agent required by a virus to replicate or spread.